LY4268989 (MORF-057) Co-Administered with Mirikizumab in Adults with Moderately to Severely Active Ulcerative Colitis: A Phase 2 Study

Prior treatment

• Have had or will need bowel resection or intestinal or intra-abdominal surgery
• Are likely to require surgery for the treatment of UC during the study

Other illness

• Have a current diagnosis of Crohn’s disease, IBD unclassified or primary sclerosing cholangitis
• Have an inherited immunodeficiency syndrome or known monogenic cause of UC-like colonic inflammation.

Other

• Have evidence of toxic megacolon, intra-abdominal abscess, or stricture or stenosis within small bowel or colon that cannot be traversed by a colonoscope or that are symptomatic.

• Have had an established diagnosis of UC of ≥3 months in before baseline
• Have moderately to severely active UC
• Have evidence of UC extending proximal to the rectum
• Participants with greater than 8 years of UC symptoms have documented evidence of having had a surveillance colonoscopy within 1 year, or according to local country or regional medical guidelines, to evaluate for polyps, dysplasia, or malignancy, prior to randomization.
• Are up-to-date on colorectal cancer surveillance
• Have an inadequate response to, loss of response to, or intolerance to Conventional therapy, Immunomodulators, Advanced therapy